Risk prediction scores for recurrence and progression of non-muscle invasive bladder cancer: an international validation in primary tumours.

scientific article

Risk prediction scores for recurrence and progression of non-muscle invasive bladder cancer: an international validation in primary tumours. is …
instance of (P31):
scholarly articleQ13442814

External links are
P819ADS bibcode2014PLoSO...996849V
P356DOI10.1371/JOURNAL.PONE.0096849
P932PMC publication ID4048166
P698PubMed publication ID24905984
P5875ResearchGate publication ID262930400

P50authorM.Luz CalleQ61758563
Esther W de Bekker-GrobQ91539297
Ellen C ZwarthoffQ91657944
Ferran AlgabaQ114329108
Ulrika SegerstenQ114335480
Mirari MárquezQ114441075
Willemien BeukersQ114441115
Nuria MalatsQ28360608
Ewout W. SteyerbergQ37828851
Lars DyrskjøtQ39568973
Francisco X RealQ54394817
Per-Uno MalmströmQ58469511
P2093author name stringTorben F Ørntoft
Moniek M Vedder
Manoils Kogevinas
P2860cites workMolecular Grade (FGFR3/MIB-1) and EORTC Risk Scores Are Predictive in Primary Non–Muscle-Invasive Bladder CancerQ63966334
Comparison of 1998 WHO/ISUP and 1973 WHO classifications for interobserver variability in grading of papillary urothelial neoplasms of the bladder. Pathological evaluation of 258 casesQ80315009
External validation and applicability of the EORTC risk tables for non-muscle-invasive bladder cancerQ83053056
The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tablesQ84215941
Bladder cancer: validating the EORTC risk tables in BCG-treated patientsQ84773139
Assessing the generalizability of prognostic informationQ33540894
Prediction models in urology: are they any good, and how would we know anyway?Q33940100
Combining molecular and pathologic data to prognosticate non-muscle-invasive bladder cancerQ34320071
External validity of risk models: Use of benchmark values to disentangle a case-mix effect from incorrect coefficientsQ34320813
Decision curve analysis: a novel method for evaluating prediction modelsQ34581068
The 2004 WHO classification of bladder tumors: a summary and commentaryQ36111995
Statistical consideration for clinical biomarker research in bladder cancerQ36124883
Assessing the performance of prediction models: a framework for traditional and novel measuresQ36617895
Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder.Q37182161
Multiple imputation in health-care databases: an overview and some applicationsQ37767543
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.Q38119345
Effect of anticoagulants and antiplatelet agents on the efficacy of intravesical BCG treatment of bladder cancer: A systematic reviewQ38166720
A comparison of imputation techniques for handling missing predictor values in a risk model with a binary outcomeQ40196067
The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference CommitteeQ40831782
Usefulness of the Spanish Urological Club for Oncological Treatment scoring model to predict nonmuscle invasive bladder cancer recurrence in patients treated with intravesical bacillus Calmette-Guérin plus interferon-α.Q44822041
Bladder cancer: epidemiology, staging and grading, and diagnosis.Q45247416
Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model.Q45816848
Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.Q51953901
Cathepsin E, maspin, Plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer.Q53177490
The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour.Q54772321
A dynamic model for the risk of bladder cancer progressionQ61732905
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P433issue6
P407language of work or nameEnglishQ1860
P304page(s)e96849
P577publication date2014-06-06
P1433published inPLOS OneQ564954
P1476titleRisk prediction scores for recurrence and progression of non-muscle invasive bladder cancer: an international validation in primary tumours
P478volume9

Reverse relations

cites work (P2860)
Q40609183Budget impact of incorporating one instillation of hexaminolevulinate hydrochloride blue-light cytoscopy in transurethral bladder tumour resection for patients with non-muscle-invasive bladder cancer in Sweden
Q58759191EORTC risk tables are more suitable for Chinese patients with nonmuscle-invasive bladder cancer than AUA risk stratification
Q91230892External validation of the EORTC and NCCN bladder cancer recurrence and progression risk calculators in a U.S. community-based health system
Q28395447Genomic Landscape of Experimental Bladder Cancer in Rodents and Its Application to Human Bladder Cancer: Gene Amplification and Potential Overexpression of Cyp2a5/CYP2A6 Are Associated with the Invasive Phenotype
Q49988036HumanMethylation450K Array-Identified Biomarkers Predict Tumour Recurrence/Progression at Initial Diagnosis of High-risk Non-muscle Invasive Bladder Cancer.
Q87618943Is it possible to stop follow-up of patients with primary T1G3 urothelial carcinoma of the bladder managed with intravesical bacille Calmette-Guérin immunotherapy?
Q35762587Methylation of HOXA9 and ISL1 Predicts Patient Outcome in High-Grade Non-Invasive Bladder Cancer
Q38424934Novel biomarkers to predict response and prognosis in localized bladder cancer
Q38400923Prediction of Multiple Recurrent Events: A Comparison of Extended Cox Models in Bladder Cancer
Q36040421Prediction of non-muscle invasive bladder cancer outcomes assessed by innovative multimarker prognostic models
Q58764414Prediction of non-muscle-invasive bladder cancer recurrence by measurement of checkpoint HLAG's receptor ILT2 on peripheral CD8 T cells
Q64262696Prediction tools in non-muscle invasive bladder cancer
Q36862682Quantitative genome-wide methylation analysis of high-grade non-muscle invasive bladder cancer.
Q42370597Risk factor assessment in high-risk, bacillus Calmette-Guérin-treated, non-muscle-invasive bladder cancer.
Q38621223Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma
Q90678306Validation of EORTC, CUETO, and EAU risk stratification in prediction of recurrence, progression, and death of patients with initially non-muscle-invasive bladder cancer (NMIBC): A cohort analysis

Search more.